STOCK TITAN

Eton Pharmaceutcials (ETON) Financials

ETON NASDAQ
FY2025 annual
Revenue $80.0M +104.9% YoY
Net Income -$4.6M n/m YoY
Free Cash Flow $10.2M +980.7% YoY
Operating Cash Flow $10.5M +986.1% YoY
Market Cap $1.8B as of Nov 20, 2026
Price / Sales 12.4x on $141.1M revenue, trailing 12 months to September 30, 2026
Price / Earnings 35.2x on $49.9M net income, trailing 12 months to September 30, 2026
Price / Book 20.2x on $86.9M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ETON SEC filings page.

Eton Pharmaceutcials, Inc. (ETON) reported $80.0M in revenue for fiscal year 2025, up 104.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ETON FY2025

Eton’s expansion now generates operating cash, but lower gross margins and a liability-heavy balance sheet still leave accounting losses.

Eton’s cash conversion improved before profitability: FY2025 operating cash flow reached $10.5M while the company still posted a net loss of $4.6M, showing that cash generation and accounting earnings were pulling in different directions. Meanwhile, gross margin fell 6.6 percentage points as sales expanded sharply, so the improvement was not driven by a richer margin structure.

The balance-sheet posture is increasingly liability-funded: liabilities were 71.6% of assets in FY2025, while the current ratio was 1.6x. That combination leaves less short-term cushion than earlier years, even as debt-to-equity fell from 1.2x to 0.8x.

FY2025 free cash flow was $10.2M against operating cash flow of $10.5M, so capital spending consumed little of the cash produced. SG&A remained 44.8% of revenue while operating margin was -1.1%, meaning scale has not fully covered commercial overhead.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 63 / 100
Financial Health Score (5 of 6 dimensions) 63/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Eton Pharmaceutcials, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
87

Eton Pharmaceutcials, Inc. held $25.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $10.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Eton Pharmaceutcials, Inc. scores 87/100 among other emerging companies.

Dilution
73

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Eton Pharmaceutcials, Inc. scores 73/100 on it among other emerging companies.

R&D Intensity
37

Eton Pharmaceutcials, Inc. spent $7.8M on research and development in fiscal year 2025, which was 9.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Eton Pharmaceutcials, Inc. scores 37/100 among other emerging companies.

Revenue Progress
80

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Eton Pharmaceutcials, Inc. scores 80/100 on it among other emerging companies.

Burn Trend
n/a

Not available for Eton Pharmaceutcials, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.

Balance Sheet
39

Eton Pharmaceutcials, Inc.'s cash, cash equivalents and investments came to $25.9M at the end of fiscal year 2025, against $66.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Eton Pharmaceutcials, Inc. scores 39/100 among other emerging companies.

Altman Z-Score Safe
15.38

Eton Pharmaceutcials, Inc. scores 15.38, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $1.8B against total liabilities of $66.0M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
5/9

Eton Pharmaceutcials, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Mixed
N/A

Eton Pharmaceutcials, Inc. reported a net loss of $4.6M while generating $10.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Eton Pharmaceutcials, Inc. reported an operating loss of $844K against $4.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$57.9M
YoY+157.9%
QoQ+54.1%
5Y CAGR+137.0%

Eton Pharmaceutcials, Inc. generated $57.9M in revenue in Q3 2026. This represents an increase of 157.9% from the same quarter a year earlier. Against the prior quarter it is up 54.1%.

EBITDA
$24.5M
YoYn/m
QoQ+72.5%
5Y CAGRn/m

Eton Pharmaceutcials, Inc.'s EBITDA was $24.5M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 72.5%.

Net Income
$35.2M
YoYn/m
QoQ+204.4%
5Y CAGRn/m

Eton Pharmaceutcials, Inc. reported $35.2M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 204.4%.

EPS (Diluted)
$1.06
YoYn/m
QoQ+202.9%

Eton Pharmaceutcials, Inc. earned $1.06 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 202.9%.

Cash & Balance Sheet

Free Cash Flow
$35.2M
YoY+200.0%

Eton Pharmaceutcials, Inc. generated $35.2M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 200.0% from the same quarter a year earlier.

Cash & Debt
$55.6M
YoY+49.9%
QoQ+107.2%
5Y CAGR+19.6%

Eton Pharmaceutcials, Inc. held $55.6M in cash against $11.2M in long-term debt as of Q3 2026.

Shares Outstanding
29M
YoY+7.5%
QoQ+0.9%
5Y CAGR+3.2%

Eton Pharmaceutcials, Inc. had 29M shares outstanding in Q3 2026. This represents an increase of 7.5% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
76.5%
YoY+41.5pp
QoQ+8.9pp
5Y change+60.9pp

Eton Pharmaceutcials, Inc.'s gross margin was 76.5% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 41.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.9 percentage points.

Operating Margin
39.7%
YoY+45.8pp
QoQ+5.7pp

Eton Pharmaceutcials, Inc.'s operating margin was 39.7% in Q3 2026, reflecting core business profitability. This is up 45.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.7 percentage points.

Net Margin
60.9%
YoY+69.4pp
QoQ+30.1pp

Eton Pharmaceutcials, Inc.'s net profit margin was 60.9% in Q3 2026, showing the share of revenue converted to profit. This is up 69.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 30.1 percentage points.

Return on Equity
40.6%
YoY+48.9pp
QoQ+15.7pp
5Y change+79.5pp

Eton Pharmaceutcials, Inc.'s quarterly ROE was 40.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 48.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 15.7 percentage points.

Capital Allocation

R&D Spending
$5.3M
YoY+374.0%
QoQ+430.8%

Eton Pharmaceutcials, Inc. invested $5.3M in research and development in Q3 2026. This represents an increase of 374.0% from the same quarter a year earlier. Against the prior quarter it is up 430.8%.

Capital Expenditures
$13K
YoY-95.4%

Eton Pharmaceutcials, Inc. invested $13K in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 95.4% from the same quarter a year earlier.

Share Buybacks

Not reported for Q3 2026.

ETON Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ETON quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$57.9M+157.9%$37.6M+98.6%$24.3M+40.4%$21.3M+82.7%$22.5M+117.5%$18.9M+108.6%$17.3M+116.9%$11.6M+59.3%
Cost of Revenue$13.6M-6.7%$12.2M+73.8%$9.5M+28.4%$8.2M+58.2%$14.6M+263.1%$7.0M+103.1%$7.4M+150.8%$5.2M+40.4%
Gross Profit$44.3M+464.0%$25.4M+113.1%$14.7M+49.4%$13.1M+102.3%$7.9M+24.6%$11.9M+111.9%$9.9M+96.9%$6.5M+78.4%
R&D Expenses$5.3M+374.0%$993K-73.2%$1.9M+61.5%$1.8M$1.1M+120.2%$3.7M+25.0%$1.2M+78.3%N/A
SG&A Expenses$16.0M+97.6%$11.6M+20.0%$10.4M+13.9%$8.9M+31.8%$8.1M+53.3%$9.7M+73.3%$9.2M+77.9%$6.7M+46.8%
Operating Income$23.0Mn/m$12.8Mn/m$2.4Mn/m$2.5M+291.7%-$1.4M-367.8%-$1.5Mn/m-$470Kn/m$629Kn/m
EBITDA$24.5Mn/m$14.2Mn/m$3.5M+552.9%$3.5M+253.8%-$354K-144.9%-$470Kn/m$543Kn/m$984Kn/m
Interest Expense$959K-20.9%$1.1M+3.1%$1.1M-2.3%$1.4M+49.3%$1.2M+474.4%$1.0M+1907.7%$1.2M+40.1%$912Kn/m
Income Tax-$12.9Mn/m$140K+112.1%$20K-73.0%-$69K-179.3%-$28Kn/m$66K+22.2%$74Kn/m$87K-64.8%
Net Income$35.2Mn/m$11.6Mn/m$1.6Mn/m$1.5Mn/m-$1.9M-407.3%-$2.6Mn/m-$1.6Mn/m-$598Kn/m
EPS (Basic)$1.23n/m$0.42n/m$0.06n/m$0.06n/m-$0.07-450.0%-$0.10n/m-$0.06n/m-$0.03n/m
EPS (Diluted)$1.06n/m$0.35n/m$0.05n/mN/A-$0.07-450.0%-$0.10n/m-$0.06n/mN/A
Diluted Shares (Avg)33M+23.7%33M+21.9%32M+17.3%N/A27M+1.3%27M+4.3%27M+4.4%N/A

ETON Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ETON quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$157.3M+50.5%$115.8M+13.9%$97.7M+16.3%$92.1M+21.0%$104.5M+191.6%$101.7M+219.5%$84.0M+172.9%$76.1M+139.8%
Current Assets$96.8M+34.4%$68.6M+0.2%$53.2M+6.6%$60.6M+47.7%$72.0M+142.0%$68.4M+169.1%$50.0M+105.9%$41.0M+52.8%
Cash & Equivalents$55.6M+49.9%$26.8M+5.8%$19.7M+12.9%$25.9M+73.7%$37.1M+83.2%$25.4M+43.4%$17.4M+4.6%$14.9M-30.2%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$11.1M-34.3%$10.1M-57.4%$14.5M+6.2%$15.4M+1.2%$16.9M+769.7%$23.8M+1050.4%$13.6M+487.6%$15.2M+1572.0%
Accounts Receivable$26.4M+102.0%$24.9M+72.2%$13.4M-18.2%$11.8M+119.3%$13.1M+134.0%$14.5M+196.6%$16.4M+286.8%$5.4M+57.2%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$70.3M-13.6%$69.2M-10.9%$67.1M+12.6%$66.0M+27.6%$81.4M+309.8%$77.7M+323.3%$59.6M+289.4%$51.7M+217.9%
Current Liabilities$54.1M+22.4%$45.1M+16.9%$44.2M+74.3%$38.5M+93.0%$44.2M+123.9%$38.6M+111.9%$25.4M+65.7%$19.9M+22.8%
Non-Current Liabilities$16.3M-56.3%$24.1M-38.4%$22.9M-33.1%$27.5M-13.5%$37.2M+29424.6%$39.1M+26878.6%$34.2Mn/m$31.7M+144209.1%
Long-Term Debt$11.2M-59.3%$19.1M-30.4%$18.9M-36.9%$21.8M-27.0%$27.6M$27.4M$30.0M$29.8Mn/m
Total Equity$86.9M+275.9%$46.6M+94.4%$30.6M+25.2%$26.2M+7.1%$23.1M+44.7%$24.0M+78.0%$24.4M+57.8%$24.4M+57.8%
Retained Earnings-$64.1Mn/m-$99.4Mn/m-$110.9Mn/m-$112.5Mn/m-$114.0Mn/m-$112.0Mn/m-$109.5Mn/m-$107.9Mn/m

Not reported in any period shown, so not listed: Goodwill.

ETON Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ETON quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$35.2M+193.0%$7.3M-8.8%$7.4M+254.3%-$11.6Mn/m$12.0M+307.4%$8.0M+534.2%$2.1Mn/m-$765K-297.7%
Depreciation & Amortization$1.4M+43.1%$1.4M+37.9%$1.1M+11.6%$1.0M+186.5%$1.0M+261.6%$1.0M+260.2%$1.0M+332.9%$355K+9.2%
Stock-Based Compensation$3.3M+203.0%N/A$1.5M+26.5%N/A$1.1M-54.2%N/A$1.2M+46.2%N/A
Capital Expenditures$13K-95.4%N/A$75Kn/m$49K+308.3%$284Kn/m$0n/m$0-100.0%$12Kn/m
Free Cash Flow$35.2M+200.0%N/A$7.3M+250.7%-$11.6Mn/m$11.7M+297.8%$8.0M+534.2%$2.1Mn/m-$777K-300.8%
Investing Cash Flow-$3.2Mn/m$5Kn/m-$15.1Mn/m-$49Kn/m-$284Kn/m$0n/m$0n/m-$38.1Mn/m
Financing Cash Flow-$3.2Mn/m-$76Kn/m$1.4M+252.5%$421K-98.7%$0n/m$0n/m$394Kn/m$33.6Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ETON Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ETON quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin76.5%+41.5pp67.6%+4.6pp60.7%+3.7pp61.6%+6.0pp35.0%-26.1pp63.0%+1.0pp57.1%-5.8pp55.6%+6.0pp
Operating Margin39.7%+45.8pp34.0%+41.8pp10.0%+12.7pp11.6%+6.2pp-6.1%-11.0pp-7.8%+24.6pp-2.7%+7.3pp5.4%+32.6pp
Net Margin60.9%+69.4pp30.8%+44.5pp6.4%+15.5pp7.0%+12.1pp-8.6%-14.6pp-13.7%+19.9pp-9.1%+1.1pp-5.1%+25.7pp
Return on Equity40.6%+48.9pp24.9%+35.6pp5.1%+11.5pp5.7%+8.1pp-8.3%-12.3pp-10.8%+11.8pp-6.4%-1.2pp-2.5%+12.1pp
Return on Assets22.4%+24.3pp10.0%+12.5pp1.6%+3.5pp1.6%+2.4pp-1.8%-3.6pp-2.5%+7.0pp-1.9%+0.8pp-0.8%+6.3pp
Current Ratio1.79+0.2x1.52-0.3x1.21-0.8x1.57-0.5x1.63+0.1x1.77+0.4x1.97+0.4x2.06+0.4x
Debt-to-Equity0.13-1.1x0.41-0.7x0.62-0.6x0.83-0.4x1.191.141.231.22+1.2x
Liabilities-to-Equity0.81-2.7x1.49-1.8x2.19-0.2x2.52+0.4x3.52+2.3x3.24+1.9x2.44+1.4x2.12+1.1x
Asset Turnover0.37+0.2x0.32+0.1x0.250.0x0.23+0.1x0.21-0.1x0.19-0.1x0.21-0.1x0.15-0.1x
FCF Margin60.8%+8.5ppN/A30.2%+18.1pp-54.5%-47.8pp52.3%+23.7pp42.0%+28.2pp12.1%+43.3pp-6.7%-12.0pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Eton Pharmaceutcials, Inc. ETON FY2025 $80.0M -$4.6M -5.8% $1.8B 63/100
BioCryst Pharmaceuticals Inc BCRX FY2025 $874.8M $263.9M 30.2% $1.9B 72/100
ANI Pharmaceuticals, Inc. ANIP FY2025 $883.4M $78.3M 8.9% $1.6B 67/100
Alvotech ALVO FY2025 $586.3M $27.9M 4.8% $1.5B 34/100
Pacira BioSciences, Inc. PCRX FY2025 $726.4M $7.0M 1.0% $1.5B 54/100
Phibro Animal Health Corporation PAHC FY2026 $1.5B $99.7M 6.6% $1.4B 62/100

Frequently Asked Questions

Eton Pharmaceutcials, Inc. (ETON) reported $80.0M in total revenue for fiscal year 2025. This represents a 104.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Eton Pharmaceutcials, Inc. (ETON) revenue grew by 104.9% year-over-year, from $39.0M to $80.0M in fiscal year 2025.

No, Eton Pharmaceutcials, Inc. (ETON) reported a net loss of $4.6M in fiscal year 2025, with a net profit margin of -5.8%.

Eton Pharmaceutcials, Inc. (ETON) had EBITDA of $3.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Eton Pharmaceutcials, Inc. (ETON) had $25.9M in cash and equivalents against $21.8M in long-term debt.

Eton Pharmaceutcials, Inc. (ETON) had a gross margin of 53.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Eton Pharmaceutcials, Inc. (ETON) had an operating margin of -1.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Eton Pharmaceutcials, Inc. (ETON) had a net profit margin of -5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Eton Pharmaceutcials, Inc. (ETON) has a return on equity of -17.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Eton Pharmaceutcials, Inc. (ETON) generated $10.2M in free cash flow during fiscal year 2025. This represents a 980.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Eton Pharmaceutcials, Inc. (ETON) generated $10.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Eton Pharmaceutcials, Inc. (ETON) had $92.1M in total assets as of fiscal year 2025, including both current and long-term assets.

Eton Pharmaceutcials, Inc. (ETON) invested $333K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Eton Pharmaceutcials, Inc. (ETON) invested $7.8M in research and development during fiscal year 2025.

Eton Pharmaceutcials, Inc. (ETON) had 27M shares outstanding as of fiscal year 2025.

Eton Pharmaceutcials, Inc. (ETON) had a current ratio of 1.57 as of fiscal year 2025, which is generally considered healthy.

Eton Pharmaceutcials, Inc. (ETON) had a debt-to-equity ratio of 0.83 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Eton Pharmaceutcials, Inc. (ETON) had a liabilities-to-equity ratio of 2.52 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Eton Pharmaceutcials, Inc. (ETON) had a return on assets of -5.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Eton Pharmaceutcials, Inc. (ETON) trades at 35.2x earnings, its market capitalization divided by $49.9M net income, trailing 12 months to September 30, 2026. The market capitalization is $1.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Eton Pharmaceutcials, Inc. (ETON) trades at 12.4x sales, its market capitalization divided by $141.1M revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.8B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Eton Pharmaceutcials, Inc. (ETON) has an Altman Z-Score of 15.38, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Eton Pharmaceutcials, Inc. (ETON) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Eton Pharmaceutcials, Inc. (ETON) reported a net loss of $4.6M while generating $10.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Eton Pharmaceutcials, Inc. (ETON) reported an operating loss of $844K against $4.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Eton Pharmaceutcials, Inc. (ETON) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Eton Pharmaceutcials, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top